205 related articles for article (PubMed ID: 11972392)
21. EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR.
Gschwantler-Kaulich D; Hudelist G; Koestler WJ; Czerwenka K; Mueller R; Helmy S; Ruecklinger E; Kubista E; Singer CF
Oncol Rep; 2005 Aug; 14(2):305-11. PubMed ID: 16012707
[TBL] [Abstract][Full Text] [Related]
22. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
23. Cyclooxygenase-2 expression in postmastectomy chest wall relapse.
Kim JH; Bossuyt V; Ponn T; Lannin D; Haffty BG
Clin Cancer Res; 2005 Jul; 11(14):5199-205. PubMed ID: 16033837
[TBL] [Abstract][Full Text] [Related]
24. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.
Merrick DT; Kittelson J; Winterhalder R; Kotantoulas G; Ingeberg S; Keith RL; Kennedy TC; Miller YE; Franklin WA; Hirsch FR
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2281-8. PubMed ID: 16609045
[TBL] [Abstract][Full Text] [Related]
25. Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas.
Bloomer CW; Kenyon L; Hammond E; Hyslop T; Andrews DW; Curran WJ; Dicker AP
Am J Clin Oncol; 2003 Aug; 26(4):S75-80. PubMed ID: 12902861
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium.
Li S; Miner K; Fannin R; Carl Barrett J; Davis BJ
Gynecol Oncol; 2004 Feb; 92(2):622-7. PubMed ID: 14766256
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Tropé CG; Nesland JM; Holm R
Anticancer Res; 1999; 19(5C):4469-74. PubMed ID: 10650794
[TBL] [Abstract][Full Text] [Related]
29. Correlative expression of cyclooxygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer.
Sugimoto T; Koizumi T; Sudo T; Yamaguchi S; Kojima A; Kumagai S; Nishimura R
Kobe J Med Sci; 2007; 53(5):177-87. PubMed ID: 18204294
[TBL] [Abstract][Full Text] [Related]
30. Cox-2 and Her2/neu co-expression in invasive bladder cancer.
Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L
Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865
[TBL] [Abstract][Full Text] [Related]
31. Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome.
Okano H; Shinohara H; Miyamoto A; Takaori K; Tanigawa N
Clin Cancer Res; 2004 Oct; 10(20):6938-45. PubMed ID: 15501972
[TBL] [Abstract][Full Text] [Related]
32. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
[TBL] [Abstract][Full Text] [Related]
33. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors.
Moroni M; Veronese S; Schiavo R; Carminati O; Sorensen BS; Gambacorta M; Siena S
Clin Cancer Res; 2001 Sep; 7(9):2770-5. PubMed ID: 11555591
[TBL] [Abstract][Full Text] [Related]
35. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
[TBL] [Abstract][Full Text] [Related]
36. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Berchuck A; Kamel A; Whitaker R; Kerns B; Olt G; Kinney R; Soper JT; Dodge R; Clarke-Pearson DL; Marks P
Cancer Res; 1990 Jul; 50(13):4087-91. PubMed ID: 1972347
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy.
Kim YB; Kim GE; Cho NH; Pyo HR; Shim SJ; Chang SK; Park HC; Suh CO; Park TK; Kim BS
Cancer; 2002 Aug; 95(3):531-9. PubMed ID: 12209745
[TBL] [Abstract][Full Text] [Related]
40. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.
Schippinger W; Dandachi N; Regitnig P; Hofmann G; Balic M; Neumann R; Samonigg H; Bauernhofer T
Am J Clin Pathol; 2007 Oct; 128(4):630-7. PubMed ID: 17875515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
